|Name||Dr. Sushmita Bhattacharya|
|Date of joining ICMR||1st Nov 2017|
|Date of joining present post||1st Nov 2017|
|Email :||durgasushmita @gmail.com; firstname.lastname@example.org|
|Graduation||BSc. (Botany Hons.) - Lady Brabourne College, Kolkata|
|Post Graduation||MSc. (Botany) - Banaras Hindu University|
|Doctoral||Ph.D. in Science (Zoology) Therapeutic Intervention of Diabetesmellitus : Chemical and Herbal Approaches; Visva Bharati University|
My vision of research is always oriented in doing meaningful work that will benefit mankind. During my PhD, I worked in the field of diabetes which have major impact in human health worldwide. Potential herbal antidiabetic compounds were isolated and characterized. One of the compounds was daidzein which is a novel target for inhibiting NFB transcription. Another important investigation was an interesting chemically synthesized anti-diabetic compound which acts as an insulin mimetic. Apart from this therapeutic approach, I have worked on mechanism of insulin resistance. A novel target of NFB which is induced by lipid has been studied known as Fetuin-A. In my postdoctoral research, I investigated the role of cancer associated mutations in BAP1 protein which is a major tumor suppressor. Mutations in BAP1 lead to protein aggregation which is a new concept of BAP1 protein function. I worked as a visiting scientist in UQCCR, Brisbane, Australia for four months on the aspect of oxidative stress in neurological disorders..
Research in my lab will be broadly directed towards understanding of host pathogen interaction and its therapeutic approach.Enteric pathogens cause cholera and severe gastric diseases. Disease develops as a result of a complex cascade of events from autophagic disruption to inflammation when infected by a pathogen. Our bacterial model will be drug resistant bacteria which can evade autophagic machinery for infiltration in host cells. Investigating the molecular mechanism behind pathogenesis will help us to develop novel therapeutics. We will use natural inhibitors from plant sources to inhibit the regulatory networks behind pathogenesis. Overarching goal of my lab is to combat cholera and gastric diseases using pharmacological sources as inhibitors.